A Randomized, Phase II Study of INCB039110 or placebo in Combination with Docetaxel in Subjects with Previously Treated Stage IIIb, IV, or Recurrent NonSmall Cell Lung Cancer

Trial Profile

A Randomized, Phase II Study of INCB039110 or placebo in Combination with Docetaxel in Subjects with Previously Treated Stage IIIb, IV, or Recurrent NonSmall Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Itacitinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 05 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 10 May 2016 Trial status completed in Spain.
    • 07 Mar 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top